Log in

NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

$24.83
+1.22 (+5.17 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$23.76
Now: $24.83
$25.04
50-Day Range
$20.23
MA: $22.13
$24.83
52-Week Range
$7.72
Now: $24.83
$25.23
Volume433,985 shs
Average Volume655,539 shs
Market Capitalization$1.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Read More
Cytokinetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.87 million
Book Value($0.19) per share

Profitability

Net Income$-121,690,000.00
Net Margins-592.61%

Miscellaneous

Employees130
Market Cap$1.48 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

How has Cytokinetics' stock been impacted by COVID-19 (Coronavirus)?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 106.4% and is now trading at $24.83. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cytokinetics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cytokinetics.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.16. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $4.92 million. View Cytokinetics' earnings history.

What price target have analysts set for CYTK?

7 Wall Street analysts have issued 12-month price targets for Cytokinetics' stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Cytokinetics' stock price to reach $26.43 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View analysts' price targets for Cytokinetics.

Has Cytokinetics been receiving favorable news coverage?

News articles about CYTK stock have trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a news impact score of -2.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View the latest news about Cytokinetics.

Are investors shorting Cytokinetics?

Cytokinetics saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 7,720,000 shares, a decrease of 6.3% from the June 15th total of 8,240,000 shares. Based on an average daily trading volume, of 867,200 shares, the short-interest ratio is currently 8.9 days. Approximately 14.2% of the company's shares are sold short. View Cytokinetics' Current Options Chain.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $24.83.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $1.48 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

What is Cytokinetics' official website?

The official website for Cytokinetics is www.cytokinetics.com.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.